Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
44.85 EUR | -2.07% | -4.51% | +71.15% |
15/03 | German arms industry receives EU millions for projects | DP |
01/03 | Transcript : AlzChem Group AG, 2023 Earnings Call, Mar 01, 2024 |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Strengths
- With a P/E ratio at 11.42 for the current year and 10.27 for next year, earnings multiples are highly attractive compared with competitors.
- With regards to fundamentals, the enterprise value to sales ratio is at 0.89 for the current period. Therefore, the company is undervalued.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
- Considering the small differences between the analysts' various estimates, the group's business visibility is good.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The three month average target prices set by analysts do not offer high potential in comparison with the current prices.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Diversified Chemicals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+71.15% | 498M | C+ | ||
-0.19% | 74.89B | B | ||
+0.03% | 46.52B | A- | ||
-4.19% | 30.82B | C | ||
+11.27% | 18.19B | B | ||
-9.44% | 11.54B | B | ||
+6.39% | 11.24B | A- | ||
-7.21% | 9.73B | - | ||
+2.79% | 9.4B | A- | ||
+6.33% | 9.37B | C- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- ACT Stock
- Ratings AlzChem Group AG